Related Experiment Video

Updated: Aug 16, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

Imatinib mesylate for refractory acute myeloblastic leukemia harboring inv(16) and a C-KIT exon 8 mutation

T Nanri, N Matsuno, T Kawakita

    Leukemia
    |July 29, 2005
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
    11:15

    Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

    Published on: September 20, 2016

    Related Experiment Videos

    Last Updated: Aug 16, 2026

    Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
    04:36

    Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

    Published on: October 17, 2025

    Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
    11:15

    Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

    Published on: September 20, 2016

    Related Concept Videos

    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

    Articles linked to this work by shared authors, journal, and citation graph.

    High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: a phase III study by JALSG.

    Leukemia·2017

    Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia.

    Blood cancer journal·2017

    PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4.

    Oncogene·2017

    Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients.

    Leukemia·2014

    Molecular and cellular analyses of HLA class II-associated susceptibility to autoimmune diseases in the Japanese population.

    Modern rheumatology·2014

    PDK1 inhibition is a novel therapeutic target in multiple myeloma.

    British journal of cancer·2013

    Circulating tumor cells identify a disseminated genomic high-risk phenotype within IMS-IMWG 2025 staging in newly diagnosed multiple myeloma.

    Leukemia·2026

    Functional characterization of snoRNA-derived RNA (sdRNA) expression in healthy hematopoiesis and acute myeloid leukemia.

    Leukemia·2026

    Csnk1a1 E98 mutations rewire signaling and metabolism in del(5q) myelodysplastic neoplasms.

    Leukemia·2026

    Patterns of clonal hematopoiesis in aplastic anemia under immunosuppressive therapy.

    Leukemia·2026

    KLF4/MLL3 complex axis drives NRBP2 transcription to eliminate acute myeloid leukemia cells.

    Leukemia·2026

    Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid Leukemia: a COMMAND registry study.

    Leukemia·2026

    Clinical Efficacy of High-Frequency Deep Repetitive Transcranial Magnetic Stimulation in the Treatment of Depression and the Predictive Role of Baseline Triglyceride Levels: A Randomized Sham-Controlled Trial.

    Clinical EEG and neuroscience·2026

    Mechanistic Basis and Therapeutic Potential of a Novel TXNIP Inhibitor in Diabetes Treatment.

    Journal of medicinal chemistry·2026

    Discovery of BRD9 PROTAC/IMiD Bifunctional Molecules as Potent Therapeutics for Hematologic Malignancies.

    Journal of medicinal chemistry·2026

    First line asciminib in chronic myeloid leukemia: a quest for the "Holy Grail" of tolerability.

    Haematologica·2026

    Successful treatment of systemic juvenile xanthogranuloma with an ABL2::GAB2 fusion using dasatinib after failure of conventional chemotherapy and MEK inhibition.

    Haematologica·2026

    Repurposing MK0873 as a non-covalent hTERT-Targeting compound: a proof of concept study.

    Frontiers in aging·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us